Robert M. Francomano Net Worth

The estimated Net Worth of Robert Francomano is at least $333 Thousand dollars as of 4 May 2020. Mr Francomano owns over 272 units of SELLAS Life Sciences Inc stock worth over $260,909 and over the last 5 years he sold SLS stock worth over $72,434.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Francomano SLS stock SEC Form 4 insiders trading

Mr has made over 4 trades of the SELLAS Life Sciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 272 units of SLS stock worth $3,131 on 4 May 2020.

The largest trade he's ever made was selling 5,064 units of SELLAS Life Sciences Inc stock on 7 February 2020 worth over $34,030. On average, Mr trades about 1,030 units every 15 days since 2019. As of 4 May 2020 he still owns at least 197,658 units of SELLAS Life Sciences Inc stock.

You can see the complete history of Mr Francomano stock trades at the bottom of the page.

Mr. Robert M. Francomano biography

Robert M. Francomano is the Sr. VP & Chief Commercial Officer at SELLAS Life Sciences Inc.

How old is Mr Francomano?

Mr Francomano is 54, he's been the Sr. VP & Chief Commercial Officer of SELLAS Life Sciences Inc since . There are 9 older and 5 younger executives at SELLAS Life Sciences Inc. The oldest executive at SELLAS Life Sciences Group Inc is David Scheinberg, 64, who is the Director.

What's Mr Francomano's mailing address?

Robert's mailing address filed with the SEC is C/O SELLAS LIFE SCIENCES GROUP, INC.,, 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036.

Insiders trading at SELLAS Life Sciences Inc

Over the last 7 years, insiders at SELLAS Life Sciences Inc have traded over $74,616 worth of SELLAS Life Sciences Inc stock. The most active insiders traders include John Varian, Jane Wasman, and David A Scheinberg. On average, SELLAS Life Sciences Inc executives and independent directors trade stock every 205 days with the average trade being worth of $6,842. The most recent stock trade was executed by Angelos M. Stergiou on 5 December 2022, trading 6,494 units of SLS stock currently worth $16,949.

What does SELLAS Life Sciences Inc do?

σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.

Complete history of Mr Francomano stock trades at Stemline Therapeutics and SELLAS Life Sciences Inc

SELLAS Life Sciences Inc executives and stock owners

SELLAS Life Sciences Inc executives and other stock owners filed with the SEC include:

• Angelos Stergiou,
  President, Chief Executive Officer, Director
• Dr. Angelos M. Stergiou M.D., ScD h.c.,
  Founder, Pres, CEO & Director
• Barbara Wood,
  Executive Vice President, General Counsel, Corporate Secretary
• Barbara A. Wood,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Dragan Cicic M.D., MBA,
  Sr. VP of Clinical Devel.
• John Burns,
  Interim Principal Accounting Officer, Vice President - Finance, Corporate Controller
• Dr. Dragan Cicic,
  Sr. VP of Clinical Devel.
• Jane Wasman,
  Independent Chairman of the Board
• John Varian,
  Independent Director
• Robert Van Nostrand,
  Independent Director
• David Scheinberg,
  Director
• Dragan Cicic,
  Senior Vice President - Clinical Development
• Jörg W. Breitkopf,
  Head of Clinical Operations
• Robert M. Francomano,
  Sr. VP & Chief Commercial Officer
• John Thomas Burns CPA,
  Sr. VP of Fin. & Chief Accounting Officer
• David D. Moser,
  VP of Legal Affairs
• Jörg W. Breitkopf,
  Head of Clinical Operations
• Dr. Christopher R. Shackleton,
  Director of Clinical and Bus. Operations
• Martin G. Baum,
  Chief Operating Officer
• John Thomas Burns CPA, CPA,
  VP of Fin., Corp. Controller & Chief Accounting Officer
• Fabio Lopez,
  Director
• Nicholas J. Sarlis,
  Chief Medical Officer and SVP
• Robert Francomano,
  Chief Commercial Officer
• Fabio Eqc Private Markets S...,
  
• Stephen F Ghiglieri,
  Director
• Gregory M Torre,
  CRO and SVP
• Fabio Eqc Private Markets S...,
  
• Gene Mack,
  CFO and Treasurer
• Katherine Bach Kalin,
  Director